Nanomedicine: Nanotechnology, Biology and Medicine
Volume 4, Issue 4 , Pages 311-317 , December 2008

Novel nanoparticles for the delivery of recombinant hepatitis B vaccine

  • Dhruba J. Bharali, PhD

      Affiliations

    • Pharmaceutical Research Institute at Albany College of Pharmacy, Rensselaer, New York
    • ,
  • Vandana Pradhan, PhD

      Affiliations

    • Roswell Park Cancer Institute, Department of Immunology, Buffalo, New York
    • ,
  • Galina Elkin, MS

      Affiliations

    • Roswell Park Cancer Institute, Department of Immunology, Buffalo, New York
    • ,
  • Wu Qi, PhD

      Affiliations

    • Roswell Park Cancer Institute, Department of Immunology, Buffalo, New York
    • ,
  • Alan Hutson, PhD

      Affiliations

    • Department of Biostatistics, Buffalo, New York, USA
    • ,
  • Shaker A. Mousa, MBA, PhD

      Affiliations

    • Pharmaceutical Research Institute at Albany College of Pharmacy, Rensselaer, New York
    • Corresponding Author InformationCorresponding author.
    • ,
  • Yasmin Thanavala, PhD

      Affiliations

    • Roswell Park Cancer Institute, Department of Immunology, Buffalo, New York

Received 22 December 2007 ,Accepted 14 May 2008.

References 

  1. Davis JP. Experience with hepatitis A and B vaccines. Am J Med. 2005;118(Suppl 10A):7S–15S
  2. Hadler SC, Margolis HS. Epidemiology of hepatitis B virus infection. In:  Ellis RW editors. Hepatitis B vaccines in clinical practice. New York: Marcel Dekker Inc; 1993;p. 141–158
  3. Cheng JF, Chisari FV, Vu TH, Hoffmann AR, Campbell TC. Repression of hepatitis B virus (HBV) transgene and HBV-induced liver injury by low protein diet. Oncogene. 1997;15:2795–2801
  4. Gupta RK, Siber GR. Adjuvants for human vaccines—current status, problems and future prospects. Vaccine. 1995;13:1263–1276
  5. Clements CJ, Griffiths E. The global impact of vaccines containing aluminum adjuvants. Vaccine. 2002;20:S24–S33
  6. Trollfors B, Bergfors E, Inerot A, O'Hagan DT, Singh M, Xie H, et al. Vaccine related itching nodules and hypersensitivity to aluminum. Vaccine. 2005;23:975–976
  7. Giudice GD, Fragapane E, Bugarini R, Hora M, Henriksson T, Palla E, et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol. 2006;13:1010–1013
  8. Spiers ID, Eyles JE, Baillie LW, Williamson ED, Alpar HO. Biodegradable microparticles with different release profiles: effect on the immune response after a single administration via intranasal and intramuscular routes. J Pharm Pharmacol. 2000;52:1195–1201
  9. Kavanagh OV, Early B, Murray M, Foster CJ, Adair BM. Antigen specific IgA and IgG responses in calves inoculated intranasally with ovalbumin encapsulated in poly(d,l-lactide-co-glycolide) microspheres. Vaccine. 2003;21:4472–4480
  10. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Del Rev. 2005;57:391–410
  11. Wikingsson L, Sjoholm I. Polyacryl starch microparticles as adjuvant in oral immunization, inducing mucosal and systemic immune responses in mice. Vaccine. 2002;20:3353–3363
  12. McNeela E, O'Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M, et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM (197) of diphtheria toxin with chitosan enhances local and systemic and TH2 responses following nasal delivery. Vaccine. 2000;19:1188–1198
  13. Van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Verhoef JC, Junginger HE. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine. 2003;21:1400–1408
  14. Kersten G, Hirshberg H. Antigen delivery systems. Expert Rev Vaccines. 2004;3:453–462
  15. Duncan JD, Gilley RM, Schafer DP, Moldoveanu Z, Mestecky Z. Poly(lactide-co glycolide) microencapsulation of vaccines for mucosal immunization. In:  Kiyono H,  Ogra PL,  McGhee JR editor. Mucosal vaccines. San Diego: Academic Press; 1996;p. 159–174
  16. Kersten GFA, Kaufmann GB. Biodegradable microspheres as vehicles for antigens. In:  Kaufmann SHE editors. Concepts in vaccine development. New York: Walter de Gruyter; 1996;p. 265–302
  17. Eldridge JH, Staas JK, Tice TR, Gilley RM. Biodegradable poly (lactide-co-glycolide) microspheres. Res Immunol. 1992;143:557–563
  18. Eldridge J, Gilley R, Staas R, Moldoveanu Z, Muelbroek J, Tice T. Biodegradable microspheres: vaccine delivery system for oral immunization. Curr Top Microbio Immunol. 1989;146:59–66
  19. Beletsi A, Panagi Z, Avgoustaki K. Biodistribution of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock coplymers. Int J Pharm. 2005;298:233–241
  20. Davis SS. Biomedical application of nanotechnology—implications for drug targeting and gene therapy. Trends Biotechnol. 1997;15:217–224
  21. Gref R, Minamitake Y, Peracchia MT, Tubetskoy V, Torchilin V, Langer R. Biodegradable long circulating polymeric nanospheres. Science. 1994;263:1600–1603
  22. Panagi Z, Beletsi A, Evagelatos G, Livaniou E, Ithakissios DS, Avgoustakis K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm. 2001;221:143–152
  23. Beletsi A, Leondiadis L, Klepetsanis P, Ithakissios DS, Avgoustakis K. Effect of preparative variables on the properties of PLGA-mPEG copolymers related to their application in controlled drug delivery. Int J Pharm. 1999;182:187–197
  24. Dong Y, Feng SS. Methoxy poly (ethylene glycol)–poly (lactide) (MPEG–PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials. 2004;25:2843–2849
  25. Gupta RK, Chang AC, Griffin P, Rivera R, Guo YY, Siber GR. Determination of protein loading in biodegradable polymer microspheres containing tetanus toxoid. Vaccine. 1997;15:672–678
  26. O'Hagan DT, Jeffery H, Davis SS. The preparation and characterization of poly (lactide-co-glycolide) microparticles II. The entrapment of a model protein using a water-in-oil-in water emulsion solvent evaporation technique. Pharm Res. 1993;10:362–368
  27. McGee JP, Singh M, Li XM, Qui H, O'Hagan DT. The encapsulation of a model protein in poly (lactide-co-gly-colide) microparticles of various sizes; an evaluation of process reproducibility. J Microencapsul. 1997;14:197–210
  28. Thanavala Y, Kong QX, Richter L, Yang YF, Arntzen CJ, Mason HS. Immunization with hepatitis B surface antigen expressed in transgenic plants. Proc Natl Acad Sci U S A. 2001;98:11539–11544
  29. Thanavala Y, Mahoney M, Scott A, Pal S, Richter L, Natarajan R, et al. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc Natl Acad Sci U S A. 2005;102:3378–3382
  30. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303:833–841
  31. Francis DP, Hadler SC, Thompson SE, Maynard JE, Ostrow DG, Altman N, et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control Multi-Center Efficacy Trial among homosexual men. Ann Intern Med. 1982;97:362–366
  32. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986;315:209–214
  33. Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties, and possible applications in drug delivery. Curr Drug Deliv. 2004;1:321–333
  34. Teixeira M, Alonso MJ, Pinto MM, Barbosa CM. Development and characterization of PLGA nanosperes and nanocapsules containing xanthone and 3-methoxyxanthone. Eur J Pharm Biopharm. 2005;59:491–500
  35. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release. 1999;57:171–185
  36. Dong Y, Feng SS. Poly (d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26:6068–6076
  37. Singh M, Li XM, McGee JP, Zamb T, Koff W, Wang CY, et al. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice: evaluation of immunogenicity in mice. Vaccine. 1997;15:475–481

 The work in the laboratory of Y. Thanavala was partly supported by developmental funds from the Roswell Park National Cancer Institute Cancer Center Support Grant CA016056.

PII: S1549-9634(08)00088-9

doi: 10.1016/j.nano.2008.05.006

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 4, Issue 4 , Pages 311-317 , December 2008

Article Tools

* Image Usage & Resolution